Effect of Single High Dose of Cholecalciferol on Serum Metabolites of Vitamin D
Vitamin D Deficiency
About this trial
This is an interventional diagnostic trial for Vitamin D Deficiency focused on measuring vitamin D, 25(OH)D3, 25(OH)D2, 3-epi-25(OH)D3, 24,25(OH)2D3, 1,25(OH)2D3
Eligibility Criteria
Inclusion Criteria:
- written, informed consent,
- age ≥ 60 years-old,
- admission to the hospital due to emergency reasons.
Exclusion Criteria:
- hypercalcemia,
- nephrolithiasis,
- kidney insufficiency,
- documented vitamin D3 metabolism disorders such as sarcoidosis, parathyroid disease or genetic defects,
- vitamin D3 supplementation within 6 months prior to the hospitalisation.
Sites / Locations
- Department of Endocrinology, Centre of Postgraduate Medical Education
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Study Group
Control Group
Participants received single, high, oral dose of vitamin D3 (120,000 IU), serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) at baseline, 3 days and 7 days after bolus dose were measured. The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA).
Serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) were measured at baseline, 3 days and 7 days after. The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA).